logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Showing 1 - 8 of 8 Items
Showing 1 - 8 of 8 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial

Bonnet MMB, Bhatt NB, Baudin E, Silva C, Michon C,  et al.
2013-04-01 • Lancet Infectious Diseases
2013-04-01 • Lancet Infectious Diseases
BACKGROUND
In countries with a high incidence of HIV and tuberculosis co-infection, nevirapine and efavirenz are widely used as antiretroviral therapy but both interact with antitube...
Journal Article
|
Research

Women experience a better long-term immune recovery and a better survival on HAART in Lao People's Democratic Republic

Bastard M, Soulinphumy K, Phimmasone P, Saadani A, Ciaffi L,  et al.
2013-01-22 • BMC Infectious Diseases
2013-01-22 • BMC Infectious Diseases
BACKGROUND
In April 2003, Médecins Sans Frontières launched an HIV/AIDS programme to provide free HAART to HIV-infected patients in Laos. Although HIV prevalence is estimated as low ...
Journal Article
|
Research

Impact of Human Immunodeficiency Virus on the Severity of Buruli Ulcer Disease: Results of a Retrospective Study in Cameroon

Christinet V, Rossel L, Serafini M, Delhumeau C, Odermatt P,  et al.
2014-04-26 • Open Forum Infectious Diseases
2014-04-26 • Open Forum Infectious Diseases
Abstract
Background.  Buruli ulcer is the third most common mycobacterial disease after tuberculosis and leprosy and is particularly f...
Journal Article
|
Research

High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy

Laurent C, Bourgeois A, Mpoudi-Ngole E, Kouanfack C, Ciaffi L,  et al.
2010-01-01 • HIV medicine
2010-01-01 • HIV medicine
OBJECTIVES: To investigate the presence of hepatitis B virus (HBV) DNA and hepatitis C virus (HCV) RNA in HIV-infected patients initiating antiretroviral therapy in Cameroon. METHODS: Ba...
Journal Article
|
Research

Impact of HIV on the Severity of Buruli Ulcer Disease: Results of a Retrospective Study in Cameroon

Christinet V, Comte E, Ciaffi L, Odermatt P, Serafini M,  et al.
2014-05-21 • Open Forum Infectious Diseases
2014-05-21 • Open Forum Infectious Diseases
Background: Buruli ulcer (BU) is the third most common mycobacterial disease after tuberculosis and leprosy and is particularly frequent in rural West and Central Africa. However, the im...
Journal Article
|
Research

Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients

Soria A, Porten K, Fampou-Toundji JC, Galli L, Mougnutou R,  et al.
2009-02-01 • Antiviral therapy
2009-02-01 • Antiviral therapy
BACKGROUND
The lack of HIV type-1 (HIV-1) viral load (VL) monitoring in resource-limited settings might favour the accumulation of resistance mutations and thus hamper second-line tr...
Journal Article
|
Research

Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in cameroon

Kouanfack C, Laurent C, Peytavin G, Ciaffi L, Ngolle M,  et al.
2008-06-01 • Journal of Acquired Immune Deficiency Syndromes (1999)
2008-06-01 • Journal of Acquired Immune Deficiency Syndromes (1999)
OBJECTIVES: To compare adherence to antiretroviral therapy using drug level monitoring and self-report and to explore the relation between these 2 methods and viral load measurements. ME...
Journal Article
|
Research

COVID-19 outbreak investigation and response in a penitentiary setting: the experience of a prison in Italy, February to April 2020

Giuliani R, Cairone C, Tavoschi L, Ciaffi L, Sebastiani T,  et al.
2021-09-01 • Eurosurveillance
2021-09-01 • Eurosurveillance
Prisons are high-risk settings for COVID-19 and present specific challenges for prevention and control. We describe a COVID-19 outbreak in a large prison in Milan between 20 February and...